English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The GenMark Dx ePlex BCID Gram-Negative (GN) panel utilizes electrowetting technology to detect the most common causes of GN bacteremia (21 targets) and 6 antimicrobial resistance (AMR) genes from positive blood culture (BC) bottles. Rapid detection of extended spectrum β-lactamases (ESBL: CTX-M & carbapenemases: KPC, NDM, IMP, VIM, OXA 23/48), and highly resistant bacteria such as  S. maltophilia  should enable early optimization of antimicrobial therapy.    Methods  In this prospective study, aliquots of positive BC bottles with GN bacteria detected on Gram stain (GS) (n=108) received standard of care (SOC) culture and antimicrobial susceptibility testing (AST). Additionally, samples were evaluated with the BCID-GN panel but only SOC results were reported in the EMR and available to inform clinical decisions. Chart reviews were performed to evaluate the impact of the BCID-GN panel on the time to organism identification, AST results, and optimization of antimicrobial therapy.Results  A total of 108 patients are included in the analysis (Table 1).  Escherichia coli  was the most common bacteria identified followed by  Klebsiella pneumoniae, Pseudomonas aeruginosa,  and  Enterobacter  species (Table 2). There were 11 (10.2%) polymicrobial bacteremias. Repeat BCs were obtained in 68 (63%) patients of which 13 (19%) were persistently positive. Eight (7%) patients had evidence of additional gram-positive (GP) pathogens. Organism identification occurred 26.7 hours faster than culture. In conjunction with GS, negative pan-GP marker data could have helped providers make the decision to remove GP antibiotic coverage in 63 (58%) patients. Narrowing from empiric meropenem could have occurred in 5 patients. Of 10 individuals infected with resistant isolates (1  S. maltophilia , 1 OXA 23/48, and 8 CTX-M) empiric therapy was ineffective in 4 (40%) cases. Optimization of antimicrobial therapy for 9 (8.3%) patients could have occurred an average of 52.4 hours earlier than standard methods.   Table 1. Patient demographics and co-morbidities.Table 2. Gram-negative bacteria frequency.Conclusion  The BCID-GN panel enabled earlier time to optimal treatment of highly resistant bacteria as well as multiple opportunities for narrowing gram negative spectrum and a higher degree of certainty in cessation of broad-spectrum gram-positive antibiotics    Disclosures    Todd P. McCarty, MD ,  Cidara  (Grant/Research Support) GenMark  (Grant/Research Support, Other Financial or Material Support, Honoraria for Research Presentation) T2 Biosystems  (Consultant)  Sixto M. Leal, Jr., MD, PhD ,  Abnova  (Grant/Research Support) AltImmune  (Grant/Research Support) Amplyx Pharmaceuticals  (Grant/Research Support) Astellas Pharmaceuticals  (Grant/Research Support) CNINE Dx  (Grant/Research Support) GenMark Diagnostics  (Grant/Research Support, Other Financial or Material Support, Honoraria- Research Presentation) IHMA  (Grant/Research Support) IMMY Dx  (Grant/Research Support) JMI/Sentry  (Grant/Research Support) mFluiDx Dx  (Grant/Research Support) SpeeDx Dx  (Grant/Research Support) Tetraphase Pharmaceuticals  (Grant/Research Support)

1022. Evaluating the Impact of GenMark Dx ePlex® Blood Culture Identification (BCID) on Gram-negative Bloodstream Infections